NCT02364479View on ClinicalTrials.gov

Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein

PHASE4CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

February 10, 2014

Primary Completion Date

July 28, 2016

Study Completion Date

August 28, 2016

Conditions

Spondyloarthritis

Interventions

DRUG

50mg Yisaipu

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week

DRUG

25mg etanercept

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week

DRUG

Placebo

The injection method and frequency of placebo is the same as the other arms.

Trial Locations (1)

510060

Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT02364479 - Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein | Biotech Hunter | Biotech Hunter